Postmastectomy Radiation Therapy Is Associated With Improved Survival in Node-Positive Male Breast Cancer: A Population Analysis.

Abstract

PURPOSE:

Because of its rarity, there are no randomized trials investigating postmastectomy radiation therapy (PMRT) in male breast cancer. This study retrospectively examines the impact of PMRT in male breast cancer patients in the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database.

METHODS AND MATERIALS:

The SEER database 8.3.2 was queried for men ages 20+ with a diagnosis of localized or regional nonmetastatic invasive ductal/lobular carcinoma from 1998 to 2013. Included patients were treated by modified radical mastectomy (MRM), with or without adjuvant external beam radiation. Univariate and multivariate analyses evaluated predictors for PMRT use after MRM. Kaplan-Meier overall survival (OS) curves of the entire cohort and a case-matched cohort were calculated and compared by the log-rank test. Cox regression was used for multivariate survival analyses.

RESULTS:

A total of 1933 patients were included in the unmatched cohort. There was no difference in 5-year OS between those who received PMRT and those who did not (78% vs 77%, respectively, P=.371); however, in the case-matched analysis, PMRT was associated with improved OS at 5 years (83% vs 54%, P<.001). On subset analysis of the unmatched cohort, PMRT was associated with improved OS in men with 1 to 3 positive nodes (5-year OS 79% vs 72% P=.05) and those with 4+ positive nodes (5-year OS 73% vs 53% P<.001). On multivariate analysis of the unmatched cohort, independent predictors for improved OS were use of PMRT: HR=0.551 (0.412-0.737) and estrogen receptor-positive disease: HR=0.577 (0.339-0.983). Predictors for a survival detriment were higher grade 3/4: HR=1.825 (1.105-3.015), larger tumor T2: HR=1.783 (1.357-2.342), T3/T4: HR=2.683 (1.809-3.978), higher N-stage: N1 HR=1.574 (1.184-2.091), N2/N3: HR=2.328 (1.684-3.218), black race: HR=1.689 (1.222-2.336), and older age 81+: HR=4.164 (1.497-11.582).

CONCLUSIONS:

There may be a survival benefit with the addition of PMRT for male breast cancer with node-positive disease.

• Authors: Matthew J Abrams, Paul P Koffer, David E Wazer, Jaroslaw T Hepel
• Journal: International journal of radiation oncology, biology, physics (Int J Radiat Oncol Biol Phys) Vol. 98 Issue 2 Pg. 384-391 (06 01 2017) ISSN: 1879-355X [Electronic] United States
• PMID: 28463158 (Publication Type: Journal Article)
• Copyright: Copyright © 2017 Elsevier Inc. All rights reserved.

Chemical References

• Receptors, Estrogen
• Receptors, Progesterone

Topics

• Adult
• Aged
• Aged, 80 and over
• Analysis of Variance
• Breast Neoplasms, Male (mortality, pathology, radiotherapy, surgery)
• Carcinoma, Ductal, Breast (mortality, pathology, radiotherapy, surgery)
• Carcinoma, Lobular (mortality, pathology, radiotherapy, surgery)
• Combined Modality Therapy (methods, mortality)
• Humans
• Kaplan-Meier Estimate
• Lymph Nodes (pathology)
• Male
• Mastectomy, Modified Radical
• Middle Aged
• Postoperative Period
• Radiotherapy, Adjuvant (mortality)
• Receptors, Estrogen (analysis)
• Receptors, Progesterone (analysis)
• Retrospective Studies
• SEER Program
• Survival Analysis